Purchase Order 75F40124P00233

Award Date 7/9/24
Potential Completion Date 12/31/24
Potential Value $41K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
France
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This $100,491 firm-fixed price purchase order was awarded by the National Institutes of Health (NIH) National Institute of Environmental Health Sciences (NIEHS) to Lonza Walkersville, Inc., a for-profit manufacturer of biological materials and laboratory supplies. The contract is for the delivery of up to 400 vials of cryopreserved No-Spin HepaRG cells, which are specialized cell lines used in toxicology research. This award supports a collaborative project between NIEHS and the Environmental...
This firm-fixed-price purchase order was awarded by the Defense Health Agency to Lonza Walkersville, Inc.'s Walkersville division, a for-profit manufacturer of specialized biological materials, laboratory equipment, and scientific services. The $3,192 contract is for the delivery of CC-2540S NHBE-Bronchial Epi Cells for B- research and does not have a set-aside designation. Lonza Walkersville holds a $10 million Blanket Purchase Agreement with the National Institutes of Health's Office of...
This is a $69,811.32 firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Lonza Walkersville, Inc. The contract is not set aside and was awarded under the agency's ARRA (American Recovery and Reinvestment Act) order for NHBE-Bronchial Epi Cells - Catalog No. CC-2541W12. Lonza Walkersville, a subsidiary of Lonza Group Ltd., is a leading provider of specialized biological materials, laboratory equipment, and scientific services to...
The federal contract award to Lonza Walkersville, Inc. is for the supply of specialized biological materials, laboratory equipment, and scientific services to the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services. The $3,672.80 firm-fixed-price contract provides for the delivery of products such as Hanks' Balanced Salt Solution, NoSpin HepaRG cells, 4D-Nucleofector systems, and the Cocoon automated cell...
This is a firm fixed-price purchase order awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a civilian agency within the U.S. Department of Health and Human Services, to Lonza Walkersville, Inc. The $3,662.36 award does not have a set-aside designation. Lonza Walkersville, a subsidiary of the global Lonza Group, is a leading provider of specialized biological materials, laboratory equipment, and scientific services to federal agencies. This contract...
This firm-fixed-price purchase order contract was awarded by the National Institute of Child Health and Human Development (NICHD), a component of the U.S. Department of Health and Human Services, to Lonza Walkersville, Inc., a for-profit manufacturer and supplier of specialized biological materials, laboratory equipment, and scientific services. The $15,882 contract provides Lonza's Walkersville division the opportunity to supply NICHD with a range of products including Hanks' Balanced Salt...
This is a firm-fixed-price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Environmental Health Sciences (NIEHS) to Lonza Walkersville, Inc., a for-profit manufacturer of biological materials, media products, laboratory supplies, and medical/scientific equipment. The $19,640.45 contract has an estimated completion date of April 18, 2024 and does not utilize a set-aside designation. Lonza Walkersville has...
This is a $5,998.00 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Lonza Walkersville, Inc., a subsidiary of the Lonza Group Ltd. The contract has an ultimate completion date of December 31, 2011 and was awarded on December 19, 2011. Lonza Walkersville, Inc. is a leading provider of specialized biological materials, laboratory equipment, and scientific services to the U.S. federal government, particularly agencies within the...
This is a federal contract award with Lonza Walkersville, Inc., a subsidiary of Lonza Group Ltd., to provide specialized biological materials, laboratory equipment, and scientific services to the National Institutes of Health (NIH). The contract, valued at $24,960.00, is a Blanket Purchase Agreement (BPA) call under a larger $10 million BPA with the NIH Office of Logistics and Acquisition Operations. Lonza Walkersville has supplied a range of products, including cell culture media, cryopreserved...
The Food and Drug Administration (FDA) awarded a $91,630 firm-fixed-price purchase order contract to Discovery Life Sciences, LLC, a small disadvantaged business, for the delivery of 110 vials of primary cryopreserved human hepatocytes. This requirement supports the FDA's National Center of Toxicological Research (NCTR) Division of Biochemical Toxicology's research into drug toxicity and metabolic enzymes. The contract has a period of performance through August 19, 2024 and was awarded under a...

This federal contract award to Lonza Walkersville, Inc. Walkersville Division, a subsidiary of the global company Lonza Group Ltd., is for the supply of Biopredic International NoSpin HepaRG cells to the Food and Drug Administration (FDA). The $40,666.00 firm-fixed-price purchase order is to support research at the National Center for Toxicological Research (NCTR) on the cytotoxicity and genotoxicity of small-molecule nitrosamines and nitrosamine drug substance-related impurities. The key requirements are that the cells must be fully differentiated, supplied in a format that does not require centrifugation and counting following thaw, and each vial must contain 8.0 million cells at over 90% viability.

This contract award is not associated with a larger vehicle, and no set-aside was used. The original solicitation was a market research effort, not a formal request for proposals. The FDA encouraged responses from small businesses, especially those that could offer domestic products, as well as other than small business concerns that could meet the stated requirements.

Generated 12/24/24, 9:37 AM